Results 171 to 180 of about 22,989,400 (391)
Interleukin 1-dependent induction of both interleukin 2 secretion and interleukin 2 receptor expression by thymoma cells. [PDF]
John W. Lowenthal+2 more
openalex +1 more source
Bone fracture healing is a complex, timely orchestrated scenario involving multiple cell types and a plethora of cytokines and regulatory factors. To gain further insight, an in vitro model to a) study macrophage polarization under mechanical load in a fibrin hydrogel and b) subsequently assess the effect of conditioned media derived from macrophages ...
Anne Géraldine Guex+4 more
wiley +1 more source
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
Steven A. Rosenberg+6 more
openalex +2 more sources
Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. [PDF]
N Nogueira+9 more
openalex +1 more source
Animal‐Free Setup of a 3D Mature Adipocyte‐Macrophage Co‐Culture to Induce Inflammation In Vitro
A completely animal‐free 3D co‐culture is developed using human fat cells and immune cells. Animal‐based materials are replaced with gellan gum hydrogel and a serum‐free medium. Immune cells are effectively activated, producing specific inflammatory signals.
Sophia Nowakowski+3 more
wiley +1 more source
This review highlights recent progress in nanocarriers targeting pattern recognition receptors (PRRs), including Toll‐like and NOD‐like receptors, for enhancing the treatment of bacterial sepsis and related complications. These nanomedicines deliver antibiotics and anti‐inflammatory agents while modulating immune responses.
Eman A. Ismail+3 more
wiley +1 more source
The contribution of interleukin-2 to effective wound healing
K. M. Doersch+2 more
semanticscholar +1 more source
Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision
Advancements in ART improve HIV‐1 patient outcomes but are unable to eliminate latent viral DNA. To address this, CXCR4‐targeted lipid nanoparticles (T‐LNPs) for delivering CRISPR‐Cas9 to excise HIV‐1 DNA in infected cells are developed. These T‐LNPs achieve ≈60% HIV‐1 DNA excision efficacy in blood and splenic tissue, demonstrating promise for ...
Sudipta Panja+6 more
wiley +1 more source